<?xml version='1.0' encoding='utf-8'?>
<document id="23602851"><sentence text="A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile." /><sentence text="Research efforts on the human immunodeficiency virus (HIV) integrase have resulted in two approved drugs" /><sentence text=" However, co-infection of HIV with Mycobacterium tuberculosis and other microbial and viral agents has introduced added complications to this pandemic, requiring favorable drug-drug interaction profiles for antiviral therapeutics targeting HIV" /><sentence text=" Cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) are pivotal determining factors in the occurrence of adverse drug-drug interactions" /><sentence text=" For this reason, it is important that anti-HIV agents, such as integrase inhibitors, possess favorable profiles with respect to CYP and UGT" /><sentence text=" We have discovered a novel HIV integrase inhibitor (compound 1) that exhibits low nM antiviral activity against a diverse set of HIV-1 isolates, and against HIV-2 and the simian immunodeficiency virus (SIV)" /><sentence text=" Compound 1 displays low in vitro cytotoxicity and its resistance and related drug susceptibility profiles are favorable" /><sentence text=" Data from in vitro studies revealed that compound 1 was not a substrate for UGT isoforms and that it was not an inhibitor or activator of key CYP isozymes" /><sentence text="" /></document>